Search This Blog

Monday, March 2, 2020

European advisory group backs Takeda’s brigatinib for type of lung cancer

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Takeda’s (TAK +0.4%) Alunbrig (brigatinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3547494-european-advisory-group-backs-takedas-brigatinib-for-type-of-lung-cancer

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.